Abstracts tagged "outcomes"

Abstract Number: 2628 • 2019 ACR/ARP Annual Meeting
Mortality Predictors in ANCA-associated Vasculitis: Experience of a Brazilian Monocentric Cohort of a Rheumatology Center
Marilia Dagostin¹, Sergio Nunes ², Samuel Shinjo ³ and Rosa Pereira ⁴, ¹University of Sao Paulo, São Paulo, Brazil, ²Univeristy Of Sao Paulo, São Paulo, ³Univeristy Of Sao Paulo, São Paulo, Brazil, ⁴Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Sao Paulo, Brazil
Background/Purpose: Mortality of patients with ANCA-associated vasculitis (AAV) is higher than the general population. There are few papers in the literature regarding the factors associated…
Abstract Number: 2872 • 2019 ACR/ARP Annual Meeting
Risk of 30-day Readmission and Adverse Events After Primary Hip or Knee Arthroplasty: A Comparison of Patients with Rheumatoid Arthritis versus Osteoarthritis Using the Nationwide Readmission Database
Ali Yazdanyar¹, Anthony Donato ², Kathleen McElwee ³, Mary Chester Wasko ⁴ and Michael Ward ⁵, ¹Lehigh Valley Hospital- Cedar Crest, Allentown, PA, ²Reading Hospital, PA, Reading, ³Reading Hospital, Reading, PA, ⁴Allegheny Health Network-West Penn Hospital, Pittsburgh, PA, ⁵NIAMS, Bethesda, MD
Background/Purpose: To assess the risk of 30-day readmission, mortality, and adverse events among adults with Rheumatoid Arthritis as compared to Osteoarthritis after primary hip or…
Abstract Number: 1381 • 2018 ACR/ARHP Annual Meeting
Association of Omeract Core Domains of Pain and Function with Patient Satisfaction after Total Joint Replacement
Susan M. Goodman¹, Bella Y. Mehta², Lisa A. Mandl³, Jackie Szymonifka¹, Mark P. Figgie⁴, Iris Navarro-Millán⁵, Mathias Bostrom⁶, Michael L. Parks⁷, Alexander McLawhorn⁸, Stephen Lyman⁷ and Jasvinder A. Singh⁹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery/Weill Cornell Medicine/Mailman School of Public Health, New York, NY, ³Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Surgery, Hospital for Special Surgery, New York, NY, ⁵Weill Cornell Medicine, New York, NY, ⁶Orthopaedic Surgery, Hospital for Special Surgery, New York, NY, ⁷Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁸Hospital for Special Surgey, New York, NY, ⁹Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Up to 20% of Total Joint Replacement (TJR) patients are dissatisfied, but this is difficult to study as it is challenging to pool data…
Abstract Number: 2673 • 2018 ACR/ARHP Annual Meeting
Different Risk Profiles for Development of Steroid-Related and Steroid-Unrelated Damage in Early Diagnosed SLE: Results from the Italian Multicenter Early Lupus Project Inception Cohort
Matteo Piga¹, Gian Domenico Sebastiani², Imma Prevete³, Florenzo Iannone⁴, Laura Coladonato⁵, Marcello Govoni⁶, Alessandra Bortoluzzi⁷, Marta Mosca⁸, Chiara Tani⁸, Andrea Doria⁹, Luca Iaccarino¹⁰, Angela Tincani¹¹, Micaela Fredi¹², Fabrizio Conti¹³, Francesca Spinelli¹⁴, Mauro Galeazzi¹⁵, Francesca Bellisai¹⁶, Anna Zanetti¹⁷, Greta Carrara¹⁸, Carlo Alberto Scirè¹⁹ and Alessandro Mathieu¹, ¹Unit and Chair of Rheumatology, University Hospital of Cagliari, Cagliari, Italy, ²Rheumatology, San Camillo Forlanini Hospital, Roma, Italy, ³Azienda Ospedaliera San Camillo of Rome, Roma, Italy, ⁴Reumatologia Universita e Policlinico di Bari, Bari, Italy, ⁵Reumatologia, Università e Policlinico di Bari, Bari, Italy, ⁶UOC of Rheumatology, University Hospital S. Anna, Cona Ferrara, Italy, ⁷Section of Rheumatology, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliera-University Hospital S. Anna, Cona Ferrara, Italy, ⁸Rheumatology Unit, University of Pisa, Pisa, Italy, ⁹University and Azienda Ospedaliera of Padova, Padova, Italy, ¹⁰Department of Medicine-DIMED, University of Padova, Padova, Italy, ¹¹Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, BRESCIA, Italy, ¹²Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, Brescia, Italy, ¹³Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy, ¹⁴Dipartimento di Medicina Interna e Specialita` Mediche, Sapienza Universita` di Roma, Roma, Italy, ¹⁵Rheumatology, University Hospital of Siena, Siena, Italy, ¹⁶UOC di Reumatologia, Azienda Ospedaliera Universitaria Senese, Siena, Italy, ¹⁷Italian Society for Rheumatology, Milano, Italy, ¹⁸Epidemiology Unit, Italian Society for Rheumatology, Milano, Italy, ¹⁹Italian Society for Rheumatology, Milan, Italy
Background/Purpose:Preventing organ damage is a major challenge in Systemic Lupus Erythematosus (SLE).To evaluate factors associated with development of steroid-related and unrelated damage in an inception…
Abstract Number: 1438 • 2018 ACR/ARHP Annual Meeting
Treatment and Response of Down Syndrome Arthropathy
Jordan T. Jones¹, Nasreen Talib², Daniel J Lovell³ and Mara L Becker⁴, ¹Rheumatology Division, Children's Mercy Kansas City, Kansas City, MO, ²General Pediatrics, Children's Mercy Kansas City, Kansas City, MO, ³Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Rheumatology, Children's Mercy Kansas City, Kansas City, MO
Background/Purpose: Of the very few studies describing Down syndrome arthropathy (DA), crude prevalence estimates indicate DA maybe as common as juvenile idiopathic arthritis (JIA), however,…
Abstract Number: 2703 • 2018 ACR/ARHP Annual Meeting
Delay in Initiation of Therapy Predicts Worse Outcomes in Scleroderma Renal Crisis
Aditi Patel¹, Kinjal Banerjee² and Soumya Chatterjee³, ¹Internal Medicine, Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic, Cleveland, OH, ³Rheumatic and Immunologic Disease, Cleveland Clinic, Cleveland, OH
Background/Purpose: Scleroderma renal crisis (SRC) is a rare complication of patients with systemic sclerosis (SSc). ACE inhibitors (ACEI) favorably alter the natural history of this…
Abstract Number: 1684 • 2018 ACR/ARHP Annual Meeting
Prolonged Remission/Low Disease Activity State Is Associated with a Better Health-Related Quality
Manuel Ugarte-Gil^1,2, Rocío Gamboa-Cárdenas³, Mariela Medina-Chinchon³, Cristina Reategui-Sokolova³, Francisco Zevallos³, Claudia Elera-Fitzcarrald^3,4, Victor R. Pimentel-Quiroz³, Erika Noriega¹, Zoila Rodriguez-Bellido^3,5, Cesar A. Pastor-Asurza^3,5, Graciela S. Alarcón^6,7 and Risto Perich-Campos^3,5, ¹Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ²Rheumatology, Universidad Científica del Sur, Lima, Peru, ³Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁴Universidad Científica del Sur, Lima, Peru, ⁵Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁶Universidad Peruana Cayetano Heredia, Lima, Peru, ⁷Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Achieving remission and low lupus disease activity state (LDAS) in systemic lupus erythematosus (SLE) patients improves their prognosis in terms of damage accrual. But,…
Abstract Number: 2707 • 2018 ACR/ARHP Annual Meeting
Scleroderma Renal Crisis: The Association of High-Dose Steroids and Poor Outcome
Nilasha Ghosh¹, Xuan Cai² and Cybele Ghossein³, ¹Internal Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Nephrology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Scleroderma renal crisis (SRC) is the most acute and life-threatening complication of scleroderma characterized by sudden increase in blood pressure and worsening kidney function.…
Abstract Number: 1747 • 2018 ACR/ARHP Annual Meeting
Long-Term Outcomes of Patients with Nonsevere Eosinophilic Granulomatosis with Polyangiitis Given Azathioprine and Glucocorticoids for Remission Induction
Xavier Puéchal¹, Christian Pagnoux², Gabriel Baron³, François Lifermann⁴, Loïk Geffray⁵, Thomas Quémeneur⁶, Jean-Luc Saraux⁷, Marie Wislez⁸, Vincent Cottin⁹, Marc Ruivard¹⁰, Nicolas Limal¹¹, Achille Aouba¹², Bernard Bonnotte¹³, Antoine Neel¹⁴, Christian Agard¹⁵, Pascal Cohen¹⁶, Benjamin Terrier¹⁷, Claire Le Jeunne¹⁷, Luc Mouthon¹, Philippe Ravaud³ and Loïc Guillevin for the French Vasculitis Study Group¹⁷, ¹Department of Internal Medicine, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France, ²Division of Rheumatology, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ³Paris Hôtel Dieu, Paris, France, ⁴Dax, Dax, France, ⁵Lisieux, Lisieux, France, ⁶Department of Internal Medicine, CH of Valenciennes, France, Valenciennes, France, ⁷Eaubonne, Eaubonne, France, ⁸Paris Tenon, Paris, Gambia, ⁹Lyon Louis Pradel, Lyon, France, ¹⁰Clermont-Ferrand, Clermont Ferrand, France, ¹¹Créteil Henri Mondor, Créteil, France, ¹²Caen, Caen, France, ¹³Dijon, Dijon, France, ¹⁴Medecine Interne, Nantes Hôtel Dieu, Nantes, France, ¹⁵Nantes Hôtel Dieu, Nantes, France, ¹⁶Department of Internal Medicine, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, ¹⁷National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France
Background/Purpose: At month 24 (M24), CHUSPAN2-trial patients with nonsevere eosinophilic granulomatosis with polyangiitis (EGPA), who received 1 yr of azathioprine (AZA) and glucocorticoids (GC) as…
Abstract Number: 2721 • 2018 ACR/ARHP Annual Meeting
Venous Thromboembolism in ANCA Associated Vasculitis. a Population-Based Cohort Study from Southern Sweden
Matina Liapi¹, David Jayne², Mårten Segelmark³ and Aladdin Mohammad⁴, ¹Medicine, Blekinge Hospital, Karlskrona, Sweden, ²Department of Medicine, University of Cambridge, Cambridge, United Kingdom, ³Clinical Sciences, Nephrology, Lund University, Lund, Sweden, ⁴Rheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden
Background/Purpose: To estimate the rate and predictors of venous thromboembolic events (VTEs) in a population-based cohort of patients with ANCA- associated vasculitis (AAV). Methods: 322…
Abstract Number: 1846 • 2018 ACR/ARHP Annual Meeting
Menarchal Status at Diagnosis and Final Height in Females with Childhood-Onset Systemic Lupus Erythematosus
Watchareewan Sontichai¹, Daniela Dominguez¹, Lawrence Ng¹, Deborah M. Levy¹, Jonathan Wasserman², Earl Silverman¹ and Linda Hiraki¹, ¹Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²Division of Endocrinology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: The diagnosis of systemic lupus erythematosus (SLE) in childhood affects growth due to disease and therapy. To date, there are few studies of final…
Abstract Number: 2779 • 2018 ACR/ARHP Annual Meeting
Long-Term Outcome and Prognostic Factors after Aortic Valve Surgery Due to Aortic Valve Regurgitation in Patients with Takayasu Arteritis
So Hye Nam¹, Dae-Hee Kim², Doo-Ho Lim³, Ji Seon Oh¹, Seokchan Hong¹, Yong-Gil Kim¹, Chang Keun Lee¹ and Bin Yoo¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), ²Division of Cardiology, Department of Internal medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), ³Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea, Republic of (South)
Background/Purpose: Aortic valve (AV) surgery is often performed for aortic regurgitation (AR) in patients with Takayasu arteritis (TA). However, data on the long-term outcomes, including…
Abstract Number: 296 • 2018 ACR/ARHP Annual Meeting
Does Care By a Multidisciplinary Team Improve Outcomes in Rheumatoid Arthritis? a Randomized Controlled Study
Manjari Lahiri^1,2, Peter P.M. Cheung^1,2, Preeti Dhanasekaran², Su Ren Wong³, Ai Yap³, Daphne Tan³, Amelia Santosa^1,2 and Phillip HC Phan², ¹Division of Rheumatology, University Medicine Cluster, National University Hospital, Singapore, Singapore, Singapore, ²Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ³Department of Rehabilitation, National University Hospital, Singapore, Singapore, Singapore
Background/Purpose: Quality standards recommend an annual review by a multidisciplinary team (MDT) for all patients with rheumatoid arthritis (RA); however, this is based on expert…
Abstract Number: 1850 • 2018 ACR/ARHP Annual Meeting
A Population Based Study of High School Academic Outcomes in Individuals with Childhood-Onset Chronic Rheumatic Diseases in Manitoba, Canada
Siok Hoon Lily Lim^1,2, Ruth Ann Marrie³, Okechukwu Ekuma⁴, Marni Brownell⁴, Christine A. Peschken⁵, Carol A Hitchon⁶, Kerstin Gerhold^7,8 and Lisa Lix⁹, ¹Children's Hospital Research Institute of Manitoba, University of Manitoba, Winnipeg, MB, Canada, ²Pediatrics, University of MAnitoba, Winnipeg, MB, Canada, ³Internal Medicine, University of Manitoba, Winnipeg, MB, Canada, ⁴Manitoba Centre for Health Policy, University of Manitoba, Winnipeg, MB, Canada, ⁵RR 149G, University of Manitoba, Winnipeg, MB, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Pediatrics, University of Manitoba, Winnipeg, MB, Canada, ⁸Faculty of Health Sciences, Children's Hospital Research Institute of Manitoba, Winnipeg, MB, Canada, ⁹Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Childhood-onset chronic rheumatic diseases (ChildCRD) are rheumatic diseases with onset <18 years old, including juvenile arthritis (JA) and systemic autoimmune rheumatic diseases (SARD). ChildCRD…
Abstract Number: 2876 • 2018 ACR/ARHP Annual Meeting
Torque Teno Virus Quantification for Functional Monitoring of Immunomodulation with Biological Compounds in the Treatment of Rheumatoid Arthritis
Paul Studenic¹, Gregor Bond², Andreas Kerschbaumer³, Manuel Bécède³, Karel Pavelka⁴, Dmitry Karateev⁵, Jutta Stieger⁶, Rudolf Puchner⁷, Ruediger Mueller⁸, Elisabeth Puchhammer-Stöckl⁹, Martina Durechova¹⁰, Michaela Loiskandl¹⁰, Thomas Perkmann¹¹, Marta Olejarova⁴, Elena Luchikhina¹², Carl-Walter Steiner¹³, Michael Bonelli¹⁰, Josef S. Smolen¹⁴ and Daniel Aletaha¹⁰, ¹Division of Rheumatology, Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Internal Medicine 3, Division of Nephrology, Medical University of Vienna, Vienna, Austria, ³Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Department of Experimental Rheumatology, 1st Faculty of Medicine, Institute of Rheumatology, Charles University in Prague, Prague, Czech Republic, ⁵Department of Rheumatology, Department of Rheumatology, Moscow Regional Research and Clinical Institute (MONIKI), Moscow, Russian Federation, ⁶2nd Deparment of Medicine, 2nd Deparment of Medicine, Hitzing Hospital, Vienna, Austria, ⁷Private Office, Wels, Austria, ⁸Division of Rheumatology, Immunology and Rehabilitation, Division of Rheumatology, Immunology and Rehabilitation, Kantonsspital St Gallen, St. Gallen, Switzerland, ⁹Institute for Virology, Institute for Virology, Medical University of Vienna, Vienna, Austria, ¹⁰Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ¹¹Department of Laboratory Medicine, Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria, ¹²Department of rheumatology, Moscow Regional Research and Clinical Institute (MONIKI), Moscow, Russian Federation, ¹³Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ¹⁴Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
Background/Purpose: Rheumatoid arthritis (RA) patients who fail to respond to methotrexate (MTX) can be subjected to an addition of biologic disease-modifying antirheumatic drug (bDMARD). Currently…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].